Search
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigational[A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen]. … Although corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.
Categories: Compounds used in a research, industrial, or household setting, Antisense Elements (Genetics)Oxymorphone
go.drugbank.com/drugs/DB01192ApprovedVet approvedIt is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). … An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity.
Categories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022. … [L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin
Sipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigational[L53418] Sipavibart gained its first global approval in Japan in December 2024.[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025. … [A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418]
Synonyms: 1-chain), disulf, Gamma1 heavy chain Homo sapiens (1-455) [VH (Homo sapiens IGHV3-9*01 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG1*03, G1m3, nG1m1Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalIn phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia. … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: JAKAVI 5 MG (TABLETS), JAKAVI® 10MG TABLETASLevopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawn[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension. … Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s.
Synonyms: (l)-PropoxyphenePhleum pratense pollen
go.drugbank.com/drugs/DB10394ApprovedInvestigationalPhleum pratense pollen allergenic extract is used in allergenic testing.
Mixtures: SLITone ULTRA D. glomerata/ L. perenne/ P. pratense/ P. pratensis/ A. odoratum, ORALAIR 100 IR + 300 IR SublingualtablettenProducts: GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT 100 TABLET, GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT TABLET, 30 ADETMinaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. … Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesSynonyms: N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine, 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholineDeuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[L51083] Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body. … [A264108] The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory
Categories: MATE 2 Inhibitors, P-glycoprotein substratesSynonyms: (3r)-3-(2,2,3,3,4,4,5,5-d8)cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile, 1h-pyrazole-1-propanenitrile, .beta.-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-Tisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalIt was granted approval by FDA in August 2017 under the market name Kymriah. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent
Categories: Genetically-modified Autologous T CellsSynonyms: Tisagenlecleucel-T, CAR.CD19-Redirected T cells